Should I buy or sell Unicycive Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unicycive Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UNCY shares. View UNCY analyst ratings or view top-rated stocks .

What is Unicycive Therapeutics' stock price target for 2024?

4 analysts have issued twelve-month price targets for Unicycive Therapeutics' stock. Their UNCY share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $5.30 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price. View analysts price targets for UNCY or view top-rated stocks among Wall Street analysts .

How have UNCY shares performed in 2024?

Unicycive Therapeutics' stock was trading at $0.8677 at the start of the year. Since then, UNCY stock has increased by 22.2% and is now trading at $1.06. View the best growth stocks for 2024 here .

When is Unicycive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our UNCY earnings forecast .

How were Unicycive Therapeutics' earnings last quarter?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) posted its earnings results on Thursday, March, 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02.

When did Unicycive Therapeutics IPO?

Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners served as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

Who are Unicycive Therapeutics' major shareholders?

Unicycive Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.60%) and Rosalind Advisors Inc. (5.41%). View institutional ownership trends .

How do I buy shares of Unicycive Therapeutics?

Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:UNCY

Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

→ He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad)

Free UNCY Stock Alerts

$1.06

+0.02 (+1.92%)

(As of 05:30 PM ET)

Compare

Today's Range: $1.05
▼
$1.08
50-Day Range: $0.97
▼
$1.52
52-Week Range: $0.47
▼
$1.82

Volume: 103,995 shs
Average Volume: 352,028 shs
Market Capitalization: $39.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.30

Unicycive Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 400.0% Upside
$5.30 Price Target
Short Interest: Healthy
2.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.63
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.47) to ($0.38) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.11 out of 5 stars

Medical Sector

572nd out of 918 stocks

Pharmaceutical Preparations Industry

261st out of 426 stocks

3.5

Analyst's Opinion

Consensus Rating
Unicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Unicycive Therapeutics has only been the subject of 3 research reports in the past 90 days.
Read more about Unicycive Therapeutics' stock forecast and price target.

3.0

Short Interest

Percentage of Shares Shorted
2.13% of the float of Unicycive Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Unicycive Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Unicycive Therapeutics has recently increased by 50.17%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Unicycive Therapeutics does not currently pay a dividend.
Dividend Growth
Unicycive Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for UNCY.

0.8

News and Social Media Coverage

News Sentiment
Unicycive Therapeutics has a news sentiment score of -0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Unicycive Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for UNCY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.10% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Unicycive Therapeutics' insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.47) to ($0.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Unicycive Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Unicycive Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Read more about Unicycive Therapeutics' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Read this before you buy AI stocks

BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts.

Starting today, you could siphon a new stream of income from this $3 billion pool of cash.

About Unicycive Therapeutics Stock (NASDAQ:UNCY)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

UNCY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

UNCY Stock News Headlines

May 17 at 6:52 AM | americanbankingnews.com

Research Analysts Issue Forecasts for Unicycive Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:UNCY)

May 15, 2024 | finanznachrichten.de

Unicycive Therapeutics, Inc.: Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024 | globenewswire.com

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

May 15, 2024 | americanbankingnews.com

Unicycive Therapeutics (NASDAQ:UNCY) Stock Rating Reaffirmed by HC Wainwright

May 14, 2024 | investorplace.com

UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024

May 13, 2024 | globenewswire.com

Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024 | finance.yahoo.com

3 Top Penny Stocks to Buy for Explosive Returns: April Edition

April 29, 2024 | finance.yahoo.com

These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler

April 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning

April 10, 2024 | globenewswire.com

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

April 4, 2024 | markets.businessinsider.com

Unicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKD

April 2, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing

March 28, 2024 | investorplace.com

UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023

March 28, 2024 | finance.yahoo.com

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

March 28, 2024 | globenewswire.com

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

March 25, 2024 | globenewswire.com

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

March 16, 2024 | investing.com

Unicycive reports progress in kidney injury treatment trial

March 14, 2024 | markets.businessinsider.com

Buy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate Prospects

March 14, 2024 | globenewswire.com

Unicycive Announces $50 Million Private Placement

March 13, 2024 | globenewswire.com

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

March 9, 2024 | finanznachrichten.de

Unicycive Therapeutics, Inc.: Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)

March 7, 2024 | globenewswire.com

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)

March 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug Designation

March 4, 2024 | globenewswire.com

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients

February 25, 2024 | benzinga.com

Unicycive Therapeutics Stock (NASDAQ:UNCY), Short Interest Report

See More Headlines

Company Calendar

Last Earnings: 3/28/2024
Today: 5/20/2024
Next Earnings (Estimated): 8/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:UNCY
CUSIP: N/A
CIK: 1766140
Web: www.unicycive.com
Phone: 650-351-4495
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.30
High Stock Price Target: $9.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +400.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,540,000.00
Net Margins: N/A
Pretax Margin: -4,525.04%
Return on Equity: N/A
Return on Assets: -92.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.71
Quick Ratio: 1.71

Sales & Book Value

Annual Sales: $680,000.00
Price / Sales: 58.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.11) per share
Price / Book: -9.64

Miscellaneous

Outstanding Shares: 37,610,000
Free Float: 28,544,000
Market Cap: $39.87 million
Optionable: Not Optionable
Beta: 2.72

Key Executives

Dr. Shalabh K. Gupta M.D. (Age 51)
MPA, Founder, Chairman, CEO & President
Comp: $1.46M
Dr. Pramod Gupta Ph.D. (Age 64)
Executive Vice President of Pharmaceutical & Business Operations
Comp: $779.18k
Mr. Douglas Jermasek M.B.A. (Age 62)
Executive Vice President of Corporate Strategy
Comp: $430.81k
Mr. John W. Townsend CPA (Age 62)
Chief Financial Officer
Comp: $197.86k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

UNCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Unicycive Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unicycive Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UNCY shares.
View UNCY analyst ratings or view top-rated stocks.
What is Unicycive Therapeutics' stock price target for 2024?: 4 analysts have issued twelve-month price targets for Unicycive Therapeutics' stock. Their UNCY share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $5.30 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for UNCY or view top-rated stocks among Wall Street analysts.
How have UNCY shares performed in 2024?: Unicycive Therapeutics' stock was trading at $0.8677 at the start of the year. Since then, UNCY stock has increased by 22.2% and is now trading at $1.06.
View the best growth stocks for 2024 here.
When is Unicycive Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our UNCY earnings forecast.

How were Unicycive Therapeutics' earnings last quarter?: Unicycive Therapeutics, Inc. (NASDAQ:UNCY) posted its earnings results on Thursday, March, 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02.
When did Unicycive Therapeutics IPO?: Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners served as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.
Who are Unicycive Therapeutics' major shareholders?: Unicycive Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.60%) and Rosalind Advisors Inc. (5.41%).
View institutional ownership trends.
How do I buy shares of Unicycive Therapeutics?: Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UNCY) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

Unicycive Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows